Share Price and Basic Stock Data
Last Updated: December 5, 2025, 5:28 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Genesis IBRC India Ltd operates within the seeds, tissue culture, and biotechnology sector. The company’s share price currently stands at ₹117, while its market capitalization is ₹152 Cr. Over the years, Genesis has faced significant revenue challenges, as evidenced by its reported sales figures. From March 2014 to March 2025, the revenue fluctuated, peaking at ₹0.39 Cr in FY 2014 and subsequently declining to ₹0.00 Cr from FY 2022 to FY 2024. However, trailing twelve months (TTM) data indicates a recent uptick with sales recorded at ₹3.67 Cr. This resurgence in sales could signify a shift in operational strategy or market conditions that may enhance future revenue generation. Despite the historical low revenue, the company’s ability to generate sales in the latest quarter reflects a potential recovery path.
Profitability and Efficiency Metrics
Genesis IBRC’s profitability metrics present a mixed picture. The company reported a net profit of ₹3.48 Cr, yielding a remarkable return on equity (ROE) and return on capital employed (ROCE), both at 51.6%. However, the operating profit margin (OPM) is strikingly high at 94.82% for TTM, suggesting that when sales are made, they are significantly profitable. The company’s operating profit for the latest fiscal year stood at ₹3.48 Cr, yet it has a history of losses, with negative operating profit reported in previous years. Efficiency indicators such as the cash conversion cycle and days payable are absent, making it difficult to assess the operational efficiency comprehensively. The interest coverage ratio (ICR) of 6.83x indicates that the company has ample capacity to cover its interest expenses, which is a positive sign for its financial health.
Balance Sheet Strength and Financial Ratios
Examining Genesis IBRC’s balance sheet reveals a precarious situation. The company reported reserves of -₹4.65 Cr and has consistently posted negative reserves since its fiscal year 2014, indicating accumulated losses. Borrowings remain at ₹0.00 Cr, showcasing a lack of debt leverage, which may limit growth opportunities. The company’s price-to-book value (P/BV) ratio is reported at 0.71x, suggesting that the stock is trading below its book value, which could attract value-oriented investors. The total liabilities amount to ₹8.83 Cr for FY 2025, against total assets of ₹8.51 Cr, indicating a thin cushion of assets over liabilities. This financial positioning raises red flags regarding leverage and liquidity, emphasizing the need for robust operational performance to strengthen the balance sheet.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Genesis IBRC indicates a stable ownership structure, with promoters holding 11.33% and the public holding a significant 88.68%. The number of shareholders has shown slight fluctuations, with a total of 1,736 shareholders reported as of September 2025. The predominance of public shareholders may suggest a lack of institutional interest, as both foreign institutional investors (FIIs) and domestic institutional investors (DIIs) are recorded as not applicable. This could imply potential concerns regarding the company’s growth prospects and operational performance. However, the stability in the promoter’s stake can instill some confidence among retail investors, as it reflects commitment. The high public ownership could also indicate that retail investors are willing to take a risk on the company’s recovery trajectory.
Outlook, Risks, and Final Insight
The outlook for Genesis IBRC hinges on its ability to sustain and grow its recent sales momentum while managing operational costs effectively. The company has demonstrated an impressive return on equity, but its historical revenue struggles and negative reserves present significant risks. Key strengths include a high operating profit margin and a strong interest coverage ratio, suggesting that profitability is achievable when sales occur. However, risks such as ongoing losses and a lack of institutional backing could hinder investor confidence and future growth. If Genesis can leverage its recent sales uptick and improve operational efficiency, it may pave the way for a more favorable financial outlook. Conversely, failure to address its historical revenue challenges and negative reserves could stifle its recovery efforts and limit investor appeal.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Genesis IBRC India Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Genomic Valley Biotech Ltd | 8.98 Cr. | 29.4 | 103/27.2 | 89.8 | 12.8 | 0.00 % | 11.8 % | 9.68 % | 10.0 |
| Genesis IBRC India Ltd | 152 Cr. | 117 | 185/16.6 | 6.42 | 0.00 % | 51.6 % | 51.6 % | 10.0 | |
| Shreeoswal Seeds & Chemicals Ltd | 123 Cr. | 13.4 | 22.8/10.7 | 12.3 | 5.23 | 0.00 % | 9.88 % | 8.41 % | 2.00 |
| Nath Bio-Genes (India) Ltd | 277 Cr. | 146 | 239/138 | 5.87 | 362 | 1.37 % | 7.35 % | 6.77 % | 10.0 |
| Continental Seeds and Chemicals Ltd | 24.5 Cr. | 22.3 | 43.0/19.3 | 31.9 | 27.0 | 0.00 % | 4.24 % | 2.87 % | 10.0 |
| Industry Average | 184.00 Cr | 65.62 | 34.97 | 82.69 | 0.27% | 16.97% | 15.87% | 8.40 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.05 | 0.01 | 0.02 | 0.05 | 0.06 | 0.02 | 0.02 | 3.69 | 0.10 | 0.02 | 0.03 | 0.02 | 0.12 |
| Operating Profit | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| OPM % | 99.46% | ||||||||||||
| Other Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.05 | -0.01 | -0.02 | -0.05 | -0.06 | -0.02 | -0.02 | -3.69 | -0.10 | 3.65 | -0.03 | -0.02 | -0.12 |
| EPS in Rs | -0.04 | -0.01 | -0.02 | -0.04 | -0.05 | -0.02 | -0.02 | -2.84 | -0.08 | 2.81 | -0.02 | -0.02 | -0.09 |
Last Updated: August 19, 2025, 2:45 pm
Below is a detailed analysis of the quarterly data for Genesis IBRC India Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Expenses, as of Jun 2025, the value is 0.12 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.02 Cr. (Mar 2025) to 0.12 Cr., marking an increase of 0.10 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is -0.12 Cr.. The value appears to be declining and may need further review. It has decreased from -0.02 Cr. (Mar 2025) to -0.12 Cr., marking a decrease of 0.10 Cr..
- For EPS in Rs, as of Jun 2025, the value is -0.09. The value appears to be declining and may need further review. It has decreased from -0.02 (Mar 2025) to -0.09, marking a decrease of 0.07.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:16 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.39 | 0.78 | 0.00 | 0.00 | 0.29 | 0.05 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 |
| Expenses | 0.55 | 0.93 | 0.07 | 0.07 | 0.49 | 0.10 | 0.10 | 0.12 | 0.12 | 0.14 | 3.80 | 0.17 | 0.19 |
| Operating Profit | -0.16 | -0.15 | -0.07 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 | 3.48 |
| OPM % | -41.03% | -19.23% | -68.97% | -100.00% | 95.37% | 94.82% | |||||||
| Other Income | 0.01 | -0.09 | 0.42 | 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.67 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.18 | 0.21 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.33 | -0.45 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | 3.48 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | -0.33 | -0.44 | 0.35 | 0.00 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | 3.50 | 3.48 |
| EPS in Rs | -1.09 | -0.62 | 0.36 | 0.00 | -0.15 | -0.04 | -0.08 | -0.09 | -0.09 | -0.11 | -2.92 | 2.69 | 2.68 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -33.33% | 179.55% | -100.00% | 75.00% | -100.00% | -20.00% | 0.00% | -16.67% | -2614.29% | 192.11% |
| Change in YoY Net Profit Growth (%) | 0.00% | 212.88% | -279.55% | 175.00% | -175.00% | 80.00% | 20.00% | -16.67% | -2597.62% | 2806.39% |
Genesis IBRC India Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 29% |
| 5 Years: | 106% |
| 3 Years: | 215% |
| TTM: | 191% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 40% |
| 3 Years: | 54% |
| 1 Year: | 152% |
| Return on Equity | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -2% |
| 3 Years: | -2% |
| Last Year: | 52% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: December 4, 2025, 2:56 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.02 | 7.12 | 9.74 | 10.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 | 13.00 |
| Reserves | -3.25 | -3.70 | -3.35 | -3.35 | -3.55 | -3.70 | -3.80 | -3.92 | -4.04 | -4.17 | -7.97 | -4.47 | -4.65 |
| Borrowings | 0.61 | 0.17 | 0.20 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Liabilities | 0.90 | 0.93 | 0.51 | 0.03 | 0.07 | 0.08 | 0.12 | 0.12 | 0.13 | 0.14 | 0.18 | 0.30 | 0.16 |
| Total Liabilities | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Fixed Assets | 1.10 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| CWIP | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Investments | -0.00 | -0.00 | -0.00 | -0.00 | 4.66 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
| Other Assets | 0.18 | 4.52 | 7.10 | 6.68 | 4.86 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
| Total Assets | 1.28 | 4.52 | 7.10 | 6.68 | 9.52 | 9.38 | 9.32 | 9.20 | 9.09 | 8.97 | 5.21 | 8.83 | 8.51 |
Below is a detailed analysis of the balance sheet data for Genesis IBRC India Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 13.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 13.00 Cr..
- For Reserves, as of Sep 2025, the value is -4.65 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -4.47 Cr. (Mar 2025) to -4.65 Cr., marking a decline of 0.18 Cr..
- For Borrowings, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. However, Reserves are negative, which is a major warning sign. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 0.16 Cr.. The value appears to be improving (decreasing). It has decreased from 0.30 Cr. (Mar 2025) to 0.16 Cr., marking a decrease of 0.14 Cr..
- For Total Liabilities, as of Sep 2025, the value is 8.51 Cr.. The value appears to be improving (decreasing). It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
- For Fixed Assets, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 8.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
- For Total Assets, as of Sep 2025, the value is 8.51 Cr.. The value appears to be declining and may need further review. It has decreased from 8.83 Cr. (Mar 2025) to 8.51 Cr., marking a decrease of 0.32 Cr..
However, the Borrowings (0.00 Cr.) are higher than the Reserves (-4.65 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.77 | -0.32 | -0.27 | -0.07 | -0.20 | -0.05 | -0.10 | -0.12 | -0.12 | -0.14 | -3.80 | -0.17 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 28.08 | 229.29 | 62.93 | 292.00 | ||||||||
| Inventory Days | 104.29 | 0.00 | 0.00 | |||||||||
| Days Payable | 156.43 | |||||||||||
| Cash Conversion Cycle | -24.07 | 229.29 | 62.93 | 292.00 | ||||||||
| Working Capital Days | -1,272.82 | 1,586.35 | 5,991.03 | 67,890.00 | ||||||||
| ROCE % | -60.55% | -16.62% | 6.88% | 0.00% | -2.48% | -0.53% | -1.08% | -1.31% | -1.33% | -1.57% | -54.83% | 51.62% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 18 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -0.03 |
| Diluted EPS (Rs.) | -0.03 |
| Cash EPS (Rs.) | 0.04 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 7.39 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 7.39 |
| Revenue From Operations / Share (Rs.) | 3.33 |
| PBDIT / Share (Rs.) | 0.14 |
| PBIT / Share (Rs.) | 0.06 |
| PBT / Share (Rs.) | 0.04 |
| Net Profit / Share (Rs.) | -0.02 |
| NP After MI And SOA / Share (Rs.) | -0.02 |
| PBDIT Margin (%) | 4.20 |
| PBIT Margin (%) | 2.02 |
| PBT Margin (%) | 1.41 |
| Net Profit Margin (%) | -0.78 |
| NP After MI And SOA Margin (%) | -0.78 |
| Return on Networth / Equity (%) | -0.35 |
| Return on Capital Employeed (%) | 0.87 |
| Return On Assets (%) | -0.27 |
| Current Ratio (X) | 3.24 |
| Quick Ratio (X) | 3.00 |
| Interest Coverage Ratio (X) | 6.83 |
| Interest Coverage Ratio (Post Tax) (X) | -0.27 |
| Enterprise Value (Cr.) | 6.58 |
| EV / Net Operating Revenue (X) | 1.52 |
| EV / EBITDA (X) | 36.12 |
| MarketCap / Net Operating Revenue (X) | 1.59 |
| Price / BV (X) | 0.71 |
| Price / Net Operating Revenue (X) | 1.59 |
After reviewing the key financial ratios for Genesis IBRC India Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 18, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 18, the value is -0.03. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 18, the value is 0.04. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 18, the value is 7.39. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 18, the value is 3.33. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 18, the value is 0.14. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 18, the value is 0.06. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 18, the value is 0.04. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 18, the value is -0.02. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 18, the value is 4.20. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 18, the value is 2.02. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 18, the value is 1.41. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 18, the value is -0.78. This value is below the healthy minimum of 8. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 18, the value is -0.35. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 18, the value is 0.87. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 18, the value is 3.24. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 18, the value is 3.00. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 18, the value is 6.83. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 18, the value is -0.27. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 18, the value is 6.58. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 18, the value is 1.52. This value is within the healthy range. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 18, the value is 36.12. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 18, the value is 0.71. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 18, the value is 1.59. This value is within the healthy range. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Genesis IBRC India Ltd:
- Net Profit Margin: -0.78%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 0.87% (Industry Average ROCE: 16.97%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -0.35% (Industry Average ROE: 15.87%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -0.27
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 3
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 34.97)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -0.78%
FAQ
What is the intrinsic value of Genesis IBRC India Ltd?
Genesis IBRC India Ltd's intrinsic value (as of 05 December 2025) is 40.55 which is 65.34% lower the current market price of 117.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 152 Cr. market cap, FY2025-2026 high/low of 185/16.6, reserves of ₹-4.65 Cr, and liabilities of 8.51 Cr.
What is the Market Cap of Genesis IBRC India Ltd?
The Market Cap of Genesis IBRC India Ltd is 152 Cr..
What is the current Stock Price of Genesis IBRC India Ltd as on 05 December 2025?
The current stock price of Genesis IBRC India Ltd as on 05 December 2025 is 117.
What is the High / Low of Genesis IBRC India Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Genesis IBRC India Ltd stocks is 185/16.6.
What is the Stock P/E of Genesis IBRC India Ltd?
The Stock P/E of Genesis IBRC India Ltd is .
What is the Book Value of Genesis IBRC India Ltd?
The Book Value of Genesis IBRC India Ltd is 6.42.
What is the Dividend Yield of Genesis IBRC India Ltd?
The Dividend Yield of Genesis IBRC India Ltd is 0.00 %.
What is the ROCE of Genesis IBRC India Ltd?
The ROCE of Genesis IBRC India Ltd is 51.6 %.
What is the ROE of Genesis IBRC India Ltd?
The ROE of Genesis IBRC India Ltd is 51.6 %.
What is the Face Value of Genesis IBRC India Ltd?
The Face Value of Genesis IBRC India Ltd is 10.0.